Treatment of subacute hepatitis with Lamivudine and intravenous Glycyrrhizin: a pilot study.

Subacute hepatitis is a common and distinct clinicopathological entity due to Hepatitis B and E viruses in India. Lamivudine has been established as a safe and effective antiviral agent for the treatment of chronic HBV hepatitis. This drug was administered orally along with intravenous (I/V) Glycyrrhizin, an immunomodulator drug, in an open pilot trial to assess its efficacy in the treatment of subacute hepatitis. The results establish the safety and efficacy of Lamivudine in combination with I.V. Glycyrrhizin in subacute Hepatitis.